NEOMATRIX

The biotech Neomatrix today announced that it has closed a seed funding of EUR 2 millions led by 2Invest AG and i2i Capital Limited. The funds will be used to support discovery and development of personalized cancer vaccines based on innovative DNA technology. Neomatrix approach combines a deep knowledge in cancer biology, the prediction of "neoantigens", i.e. the flags that allow the immune system to

Also known as: NEOMATRIX Biotech SRL, NEOMATRIX SRL

VAT numbers: 15698291000

Primary location: Rome